Works matching IS 11738804 AND DT 2018 AND VI 32 AND IP 2
Results: 11
Interleukin-1 Blockade in Cardiovascular Diseases: From Bench to Bedside.
- Published in:
- BioDrugs, 2018, v. 32, n. 2, p. 111, doi. 10.1007/s40259-018-0274-5
- By:
- Publication type:
- Article
Benefit Versus Risk Assessment of Rotavirus Vaccination in France: A Simulation and Modeling Analysis.
- Published in:
- BioDrugs, 2018, v. 32, n. 2, p. 139, doi. 10.1007/s40259-018-0273-6
- By:
- Publication type:
- Article
Comprehensive Physicochemical and Biological Characterization of the Proposed Biosimilar Darbepoetin Alfa, LBDE, and Its Originator Darbepoetin Alfa, NESP<sup>®</sup>.
- Published in:
- BioDrugs, 2018, v. 32, n. 2, p. 153, doi. 10.1007/s40259-018-0272-7
- By:
- Publication type:
- Article
Authors’ Reply to Dr. Riccardo Perfetti: “LY2963016 Insulin Glargine: A Review in Type 1 and 2 Diabetes”.
- Published in:
- 2018
- By:
- Publication type:
- Letter to the Editor
Comment on: LY2963016 Insulin Glargine: A Review in Type 1 and 2 Diabetes.
- Published in:
- 2018
- By:
- Publication type:
- Letter to the Editor
Correction to: LY2963016 Insulin Glargine: A Review in Type 1 and 2 Diabetes.
- Published in:
- 2018
- By:
- Publication type:
- Correction Notice
Correction to: Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years’ Experience Gained.
- Published in:
- 2018
- By:
- Publication type:
- Correction Notice
Targeting Neoantigens for Personalised Immunotherapy.
- Published in:
- BioDrugs, 2018, v. 32, n. 2, p. 99, doi. 10.1007/s40259-018-0267-4
- By:
- Publication type:
- Article
Guselkumab for the Treatment of Psoriasis.
- Published in:
- BioDrugs, 2018, v. 32, n. 2, p. 119, doi. 10.1007/s40259-018-0265-6
- By:
- Publication type:
- Article
Plasma Pharmacokinetics of Valanafusp Alpha, a Human Insulin Receptor Antibody-Iduronidase Fusion Protein, in Patients with Mucopolysaccharidosis Type I.
- Published in:
- BioDrugs, 2018, v. 32, n. 2, p. 169, doi. 10.1007/s40259-018-0264-7
- By:
- Publication type:
- Article
Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years’ Experience Gained.
- Published in:
- BioDrugs, 2018, v. 32, n. 2, p. 129, doi. 10.1007/s40259-018-0262-9
- By:
- Publication type:
- Article